It Seems Boston Scientific Corporation (BSX) Will Go Up. Just Reaches 52-Week High

June 12, 2018 - By Henry Gaston

Boston Scientific Corporation (NYSE:BSX) Logo

Investors sentiment decreased to 0.96 in Q1 2018. Its down 0.38, from 1.34 in 2017Q4. It worsened, as 42 investors sold Boston Scientific Corporation shares while 181 reduced holdings. 60 funds opened positions while 153 raised stakes. 1.18 billion shares or 0.46% less from 1.18 billion shares in 2017Q4 were reported.
X Mgmt Ltd reported 0.02% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Moreover, Atlantic Trust Gru has 0% invested in Boston Scientific Corporation (NYSE:BSX). 55,820 were reported by Rampart Invest Mngmt Ltd Liability Company. Moreover, Kepos Capital L P has 0.13% invested in Boston Scientific Corporation (NYSE:BSX). 169,940 were accumulated by Trexquant Invest L P. Moreover, Comerica Securities Incorporated has 0.05% invested in Boston Scientific Corporation (NYSE:BSX) for 14,433 shares. Parthenon Ltd Liability Company reported 0.08% stake. Captrust Fin Advisors holds 1,535 shares. First Mercantile Com reported 0.04% in Boston Scientific Corporation (NYSE:BSX). Optimum Inv Advsr holds 0% or 400 shares. Spc Fincl Incorporated reported 0.21% in Boston Scientific Corporation (NYSE:BSX). Fernwood Invest Mgmt Ltd has invested 0.66% in Boston Scientific Corporation (NYSE:BSX). New Mexico Educational Retirement Board holds 130,862 shares. Da Davidson And holds 0.01% or 23,339 shares in its portfolio. Gemmer Asset Mgmt Ltd Limited Liability Company owns 0.04% invested in Boston Scientific Corporation (NYSE:BSX) for 3,912 shares.

Since December 29, 2017, it had 0 insider buys, and 20 sales for $9.49 million activity. 15,835 shares were sold by Phalen Michael P., worth $399,865 on Friday, December 29. Sorenson John Bradley had sold 14,150 shares worth $381,949. Ballinger Kevin J. had sold 31,056 shares worth $931,680 on Monday, May 7. 20,015 shares were sold by Thepaut Eric Francis Yves, worth $603,368 on Thursday, May 17. $225,413 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Butcher Arthur C. The insider Brennan Daniel J. sold $1.68M.

The stock of Boston Scientific Corporation (NYSE:BSX) hit a new 52-week high and has $37.04 target or 9.00 % above today’s $33.98 share price. The 8 months bullish chart indicates low risk for the $46.89B company. The 1-year high was reported on Jun, 12 by Barchart.com. If the $37.04 price target is reached, the company will be worth $4.22B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.99% or $0.34 during the last trading session, reaching $33.98. About 9.80M shares traded or 30.83% up from the average. Boston Scientific Corporation (NYSE:BSX) has risen 11.19% since June 12, 2017 and is uptrending. It has underperformed by 1.38% the S&P500.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on July, 26. They expect $0.34 earnings per share, up 6.25 % or $0.02 from last year’s $0.32 per share. BSX’s profit will be $469.14 million for 24.99 P/E if the $0.34 EPS becomes a reality. After $0.33 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 3.03 % EPS growth.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Among 14 analysts covering Boston Scientific (NYSE:BSX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Boston Scientific has $3600 highest and $27 lowest target. $32.93’s average target is -3.09% below currents $33.98 stock price. Boston Scientific had 20 analyst reports since January 3, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Thursday, April 26 by JP Morgan. The firm earned “Hold” rating on Friday, February 2 by Jefferies. The firm has “Overweight” rating given on Monday, March 19 by Morgan Stanley. The firm earned “Buy” rating on Tuesday, January 9 by Leerink Swann. Raymond James maintained the shares of BSX in report on Thursday, April 26 with “Strong Buy” rating. The rating was maintained by Jefferies on Wednesday, April 25 with “Hold”. The rating was maintained by Needham on Thursday, February 1 with “Buy”. RBC Capital Markets maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, February 1 with “Buy” rating. The stock has “Buy” rating by Argus Research on Thursday, June 7. Stifel Nicolaus maintained Boston Scientific Corporation (NYSE:BSX) on Wednesday, April 25 with “Buy” rating.

More notable recent Boston Scientific Corporation (NYSE:BSX) news were published by: Benzinga.com which released: “32 Stocks Moving In Monday’s Mid-Day Session” on June 11, 2018, also Benzinga.com with their article: “Boston Scientific Halted On Stryker Takeover Approach” published on June 11, 2018, Streetinsider.com published: “JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13F” on May 15, 2018. More interesting news about Boston Scientific Corporation (NYSE:BSX) were released by: Streetinsider.com and their article: “Wall Street ekes out gains ahead of Singapore summit” published on June 11, 2018 as well as Benzinga.com‘s news article titled: “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: June 12, 2018.

Boston Scientific Corporation develops, makes, and markets medical devices for use in various interventional medical specialties worldwide. The company has market cap of $46.89 billion. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. It has a 447.11 P/E ratio. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Boston Scientific Corporation (NYSE:BSX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: